Antitumor efficacy of regional oncolytic viral therapy for peritoneally disseminated cancer

Journal of Molecular Medicine

Volumn 78, Issue 3, 2000, Pages 166-174

  Bennett, Joseph J ^a   Kooby, David A ^a   Delman, Keith ^a   McAuliffe, Priscilla ^a   Halterman, Marc W ^b   Federoff, Howard ^b   Fong, Yuman ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Gene therapy; Herpes simplex virus; Peritoneal tumor; Stomach cancer

Indexed keywords

ONCOLYTIC VIRUS;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; DISSEMINATED CANCER; GENE THERAPY; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; PERITONEUM METASTASIS; POLYMERASE CHAIN REACTION; STOMACH CANCER; VIRUS STRAIN;

EID: 0034082389     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001090000092     Document Type: Article

References (41)

1. 1. Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics, 1998. CA Cancer J Clin 49:8-31
2. 2. Wisbeck WM, Becher EM, Russell AH (1986) Adenocarcinoma of the stomach: autopsy observations with therapeutic implications for the radiation oncologists. Radiother Oncol 7: 13-18
3. 3. Averbach AM, Jacquet P (1996) Strategies to decrease the incidence of intra-abdominal recurrence in resectable gastric cancer. Br J Surg 83:726-733
4. 4. Chu DZJ, Lang NP, Thompson C, Osteen PK, Westbrook KC (1989) Peritoneal carcinomatosis in nongynecologic malignancy: a prospective study of prognostic factors. Cancer 63:364-367
5. 5. Kelsen D (1996) Adjuvant and neoadjuvant therapy for gastric cancer. Semin Oncol 23:379-389
6. 6. Yu W, Whang I, Averbach A, Chang D, Sugarbaker PH (1998) Morbidity and mortality of early postoperative intraperitoneal chemotherapy as adjuvant therapy for gastric cancer. Am Surg 64:1104-1108
7. 7. Hamazoe R, Maeta M, Kaibara N (1994) Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Cancer 73:2048-2052
8. 8. Sautner T, Hofbauer F, Depisch D, et al (1994) Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 12:970-974
9. 9. Alvarez RD, Curiel DT (1997) A phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV-TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients. Hum Gene Ther 8:597-613
10. 10. Lechanteur C, Princen F, Lo Bue S, Detroz B, Fillet G, Gielen J, Bours V, Merville MP (1997) HSV-1 thymidine kinase gene therapy for colorectal adenocarcinoma-derived peritoneal carcinomatosis. Gene Ther 4:1189-1194
11. 11. Smythe WR, Kaiser LR, Hwang HC, Amin KM, Pilewski JM, Eck SJ, Wilson JM, Albelda SM (1994) Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thorac Surg 57:1395-1401
12. 12. Chambers R, Gillespie GY, Soroceanu L, Andreansky S, Chatterjee S, Chou J, Roizman B, Whitley RJ (1995) Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc Natl Acad Sci USA 92:1411-1415
13. 13. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL (1995) Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1:938-943
14. 14. Yazaki T, Manz HJ, Rabkin SD, Martuza RL (1995) Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res 55:4752-4756
15. 15. Carroll NM, Chiocca EA, Takahashi K, Tanabe KK (1996) Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg 224:323-329
16. 16. Randazzo BP, Bhat MG, Kesari S, Fraser NW, Brown SM (1997) Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant. J Invest Dermatol 108:933-937
17. 17. Toda M, Rabkin SD, Martuza RL (1998) Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther 9:2177-2185
18. 18. Kucharczuk JC, Randazzo B, Chang MY, Amin KM, Elshami AA, Sterman DH, Rizk NP, Molnar-Kimber KL, Brown SM, MacLean AR, Litzky LA, Fraser, NW, Albelda SM, Kaiser LR (1997) Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma. Cancer Res 57:466-471
19. 19. Chou J, Kern ER, Whitley RJ, Roizman B (1990) Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 250:1262-1266
20. 20. Whitley RJ, Kern ER, Chatterjee S, Chou J, Roizman B (1993) Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models. J Clin Invest 91:2837-2843
21. 21. Goldstein DJ, Weller SK (1988) Factor (s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology 166:41-51
22. 22. Goldstein DJ, Weller SK (1988) Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 62:196-205
23. 23. Kramm CM, Chase M, Herrlinger U, Jacobs A, Pechan PA, Rainov NG, Sena-Esteves M, Aghi M, Barnett FH, Chiocca EA, Breakefield XO (1997) Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther 8:2057-2068
24. 24. Yashiro M, Chung YS, Nishimura S, Inoue T, Sowa M (1996) Peritoneal metastatic model for human scirrhous gastric carcinoma in nude mice. Clin Exp Metastasis 14:43-54
25. 25. Chou J, Roizman B (1992) The gamma 1 (34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programmed cell death in neuronal cells. Proc Natl Acad Sci USA 89:3266-3270
26. 26. He B, Gross M, Roizman B (1997) The gamma (1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1 alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proc Natl Acad Sci USA 94:843-848
27. 27. Yoon SS, Carroll NM, Chiocca EA, Tanabe KK (1998) Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector. Ann Surg 228:366-372
28. 28. Andreansky SS, He B, Gillespie GY, Soroceanu L, Markert J, Chou J, Roizman B, Whitley RJ (1996) The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci USA 93: 11313-11318
29. 29. Andreansky S, Soroceanu L, Flotte ER, Chou J, Markert JM, Gillespie, GY, Roizman B, Whitley RJ (1997) Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res 57: 1502-1509
30. 30. Kooby DA, Carew JF, Halterman MW, Mack JE, Bertino JR, Blumgart LH, Federoff HJ, Fong Y (1999) Oncolytic viral therapy for human colorectal cancer and liver metastases using a multimutated herpes simplex virus type-1 (G207). FASEB J 6:499-504
31. 31. Gunderson L, Sosin H (1982) Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinico pathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 8:1-11
32. 32. Tanida O, Kaneshima S, Litsuka Y, Kuda H, Kiyasu Y, Koga S (1981) Viability of intraperitoneal free cancer cells in patients with gastric cancer. Acta Cytol 26:681-687
33. 33. Iitsuka Y, Kaneshima S, Tanida O, Takeuchi T, Koga S (1979) Intraperitoneal free cancer cells and their viability in gastric cancer. Cancer 44:1476-1480
34. 34. Iitsuka Y, Shiota S, Matsui T, Murata Y, Kimura A, Koga S (1990) Relationship between the cytologic characteristics of intraperitoneal free cancer cells and the prognosis in patients with gastric cancer. Acta Cytol 34:437-442
35. 35. Burke E, Karpeh M, Conlon K, Brennan FM (1998) Peritoneal lavage cytology in gastric cancer: an independent predictor of outcome. Ann Surg Oncol 5:411-415
36. 36. Yu W, Whang I, Suh I, Averbach A, Chang D, Sugarbaker, PH (1998) Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 228:347-354
37. 37. Wils J (1999) The treatment of advanced gastric cancer. Semin Oncol 3:397-406
38. 38. Chung RY, Saeki Y, Chiocca EA (1999) B-myb promoter retargeting of herpes simplex virus gamma 34.5 gene-mediated virulence toward tumor and cycling cells. J Virol 73:7556-7564
39. 39. Chahlavi A, Todo T, Martuza RL, Rabkin SD (1999) Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1:162-169
40. 40. Toda M, Martuza RL, Kojima H, Rabkin SD (1998) In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J Immunol 160:4457-4464
41. 41. Roizman B, Markovitz N (1997) Herpes simplex virus virulence: the functions of the gamma (1)34.5 gene. J Neurovirol 3 [Suppl 1]:S1-S2